59 research outputs found
Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia
PURPOSE
The applicability of FLT3-internal tandem duplications (FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of FLT3-ITD during relapse. Here, we comprehensively investigated the impact of next-generation sequencing (NGS)-based FLT3-ITD MRD detection on treatment outcome in a cohort of patients with newly diagnosed AML in relation to established prognostic factors at diagnosis and other MRD measurements, ie, mutant NPM1 and multiparameter flow cytometry.
METHODS
In 161 patients with de novo FLT3-ITD AML, NGS was performed at diagnosis and in CR after intensive remission induction treatment. FLT3-ITD MRD status was correlated with the cumulative incidence of relapse and overall survival (OS).
RESULTS
NGS-based FLT3-ITD MRD was present in 47 of 161 (29%) patients with AML. Presence of FLT3-ITD MRD was associated with increased risk of relapse (4-year cumulative incidence of relapse, 75% FLT3-ITD MRD v 33% no FLT3-ITD MRD; P < .001) and inferior OS (4-year OS, 31% FLT3-ITD MRD v 57% no FLT3-ITD MRD; P < .001). In multivariate analysis, detection of FLT3-ITD MRD in CR confers independent prognostic significance for relapse (hazard ratio, 3.55; P < .001) and OS (hazard ratio 2.51; P = .002). Strikingly, FLT3-ITD MRD exceeds the prognostic value of most generally accepted clinical and molecular prognostic factors, including the FLT3-ITD allelic ratio at diagnosis and MRD assessment by NGS-based mutant NPM1 detection or multiparameter flow cytometry.
CONCLUSION
NGS-based detection of FLT3-ITD MRD in CR identifies patients with AML with profound risk of relapse and death that outcompetes the significance of most established prognostic factors at diagnosis and during therapy, and furnishes support for FLT3-ITD as a clinically relevant biomarker for dynamic disease risk assessment in AML
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma:an open-label phase 2 trial
Background: The outcome of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study was to prospectively investigate the efficacy and safety of Ixazomib-Daratumumab-low-dose dexamethasone (Ixa-Dara-dex) in NDMM intermediate-fit patients. Methods: In this phase II multicenter HOVON-143 study, IMWG Frailty index based intermediate-fit patients, were treated with 9 induction cycles of Ixa-Dara-dex, followed by maintenance with ID for a maximum of 2 years. The primary endpoint was overall response rate on induction treatment. Patients were included from October 2017 until May 2019. Trial Registration Number: NTR6297. Findings: Sixty-five patients were included. Induction therapy resulted in an overall response rate of 71%. Early mortality was 1.5%. At a median follow-up of 41.0 months, median progression-free survival (PFS) was 18.2 months and 3-year overall survival 83%. Discontinuation of therapy occurred in 77% of patients, 49% due to progression, 9% due to toxicity, 8% due to incompliance, 3% due to sudden death and 8% due to other reasons. Dose modifications of ixazomib were required frequently (37% and 53% of patients during induction and maintenance, respectively), mainly due to, often low grade, polyneuropathy. During maintenance 23% of patients received daratumumab alone. Global quality of life (QoL) improved significantly and was clinically relevant, which persisted during maintenance treatment. Interpretation: Ixazomib-Daratumumab-low-dose dexamethasone as first line treatment in intermediate-fit NDMM patients is safe and improves global QoL. However, efficacy was limited, partly explained by ixazomib-induced toxicity, hampering long term tolerability of this 3-drug regimen. This highlights the need for more efficacious and tolerable regimens improving the outcome in vulnerable intermediate-fit patients. Funding: Janssen Pharmaceuticals, Takeda Pharmaceutical Company Limited.</p
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Treatment choice according to the individual conditions remains challenging, particularly in older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The impact of performance status, comorbidities, and physical functioning on survival is not well defined for patients treated with hypomethylating agents. Here we describe the impact of performance status (14% ECOG performance status 2), comorbidity (40% HCT-comorbidity index ≥ 2), and physical functioning (41% short physical performance battery  76 years was significantly associated with reduced OS (HR 1.58; p = 0.043) and female sex was associated with superior OS (HR 0.62; p = 0.06). We further compared the genetic profiles of these subgroups. This revealed comparable mutational profiles in patients younger and older than 76 years, but, interestingly, revealed significantly more prevalent mutated ASXL1, STAG2, and U2AF1 in male compared to female patients. In this cohort of older patients treated with decitabine age and sex, but not comorbidities, physical functioning or cytogenetic risk were associated with overall survival
Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds
Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in phase of the study in 22 patients, 231 eligible patients with AML above 65 years of age (median 70, range 66–81) were randomly assigned in this open label randomized Phase II study to receive standard chemotherapy (3+7) with or without tosedostat at the selected daily dose of 120 mg (n = 116), days 1–21. In the second cycle, patients received cytarabine 1000 mg/m2 twice daily on days 1-6 with or without tosedostat. CR/CRi rates in the 2 arms were not significantly different (69% (95% C.I. 60–77%) vs 64% (55–73%), respectively). At 24 months, event-free survival (EFS) was 20% for the standard arm versus 12% for the tosedostat arm (Cox-p = 0.01) and overall survival (OS) 33% vs 18% respectively (p = 0.006). Infectious complications accounted for an increased early death rate in the tosedostat arm. Atrial fibrillation w
Two Cases of Q-Fever in Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder accounting for about 2% of all leukemias. The clinical course is indolent, however HCL patients are particularly susceptible to infections. Here we report two cases of Q-fever as first manifestation of disease in two patients affected by HCL. Both patients described in this report showed an unusually sluggish clinical response to the antibiotic treatment with ciprofloxacin probably because of the marked immunodeficiency. However, treatment of HCL with cladribine administered soon after the resolution of QF pneumonitis was uneventful and led to a complete remission in both cases. Most probably the association of Coxiella burnetii (CB) infection and HCL that we observed in two patients is due to chance. However, a hairy cell resembling transformation of freshly isolated human peripheral blood lymphocytes upon CB has been showed. We think that the possibility of CB infection in febrile HCL patient should be always taken in mind, especially in endemic areas. In addition the potential for such infections to become chronic in HCL patients should not be overlooked and the reporting of further cases should be encouraged
Clinical and economic impact of compression in the acute phase of deep vein thrombosis
Item does not contain fulltex
Psychological distress among patients with lymphoma: the association with personality and coping strategies
Background: Up to one-quarter of patients with lymphoma experience persisting levels of psychological distress. This study aims to examine the extent to which personality traits and coping strategies, separately and together, are associated with psychological distress among patients with lymphoma, controlling for sociodemographic and clinical characteristics. Methods: A population-based sample of patients with lymphoma, selected from the Netherlands Cancer Registry (NCR), was invited to complete a questionnaire about psychological distress, personality, and coping strategies (Mental Adjustment to Cancer). Sociodemographic and clinical data were retrieved from the NCR. Multivariable linear regression models were constructed to assess the unique variance in psychological distress explained by personality traits and coping strategies separately and together. Results: A total of 456 patients completed the questionnaire (51%), the average age was 65 years, 64% were male, and 17% reported psychological distress. Of sociodemographic and clinical characteristics, comorbidity (β = .14, P < .001) and age (β = −.10, P = .03) were independently associated with psychological distress. In addition, of personality traits, only neuroticism was related to psychological distress (neuroticism, β = .43, P < .001). Furthermore, the coping styles anxious preoccupation (β = .12, P = .01) and helplessness/hopelessness (β = .30, P < .001) were associated with more psychological distress, whereas avoidance was associated to less psychological distress (β = −.09, P = .01). Conclusions: In conclusion, besides comorbidity and age, personality traits—in particular neuroticism—and the coping strategies helplessness/hopelessness, anxious preoccupation, and avoidance were significantly independently associated with psychological distress. Unlike personality, coping strategies are considered to be changeable and could be targeted by interventions such as cognitive behavioral therapy
Further validation and simplification of the Wells clinical decision rule in pulmonary embolism
The Wells rule is a widely applied clinical decision rule in the diagnostic work-up of patients with suspected pulmonary embolism (PE). The objective of this study was to replicate, validate and possibly simplify this rule. We used data collected in 3,306 consecutive patients with clinically suspected PE to recalculate the odds ratios for the variables in the rule, to calculate the proportion of patients with PE in the probability categories, the area under the ROC curve and the incidence of venous thromboembolism during follow-up. We compared these measures with those for a modified and a simplified version of the decision rule. In the replication, the odds ratios in the logistic regression model were found to be lower for each of the seven individual variables (p = 0.02) but the proportion of patients with PE in the probability categories in our study group were comparable to those in the original derivation and validation groups. The area under the ROC of the original, modified and simplified decision rule was similar: 0.74 (p = 0.99; p = 0.07). The venous thromboembolism incidence at three months in the group of patients with a Wells score < or = 4 and a normal D-dimer was 0.5%, versus 0.3% with a modified rule and 0.5% with a simplified rule. The proportion of patients safely excluded for PE was 32%, versus 31% and 30%, respectively. This study further validates the diagnostic utility of the Wells rule and indicates that the scoring system can be simplified to one point for each variabl
Psychological distress among patients with lymphoma: the association with personality and coping strategies
Background: Up to one-quarter of patients with lymphoma experience persisting levels of psychological distress. This study aims to examine the extent to which personality traits and coping strategies, separately and together, are associated with psychological distress among patients with lymphoma, controlling for sociodemographic and clinical characteristics. Methods: A population-based sample of patients with lymphoma, selected from the Netherlands Cancer Registry (NCR), was invited to complete a questionnaire about psychological distress, personality, and coping strategies (Mental Adjustment to Cancer). Sociodemographic and clinical data were retrieved from the NCR. Multivariable linear regression models were constructed to assess the unique variance in psychological distress explained by personality traits and coping strategies separately and together. Results: A total of 456 patients completed the questionnaire (51%), the average age was 65 years, 64% were male, and 17% reported psychological distress. Of sociodemographic and clinical characteristics, comorbidity (β = .14, P < .001) and age (β = −.10, P = .03) were independently associated with psychological distress. In addition, of personality traits, only neuroticism was related to psychological distress (neuroticism, β = .43, P < .001). Furthermore, the coping styles anxious preoccupation (β = .12, P = .01) and helplessness/hopelessness (β = .30, P < .001) were associated with more psychological distress, whereas avoidance was associated to less psychological distress (β = −.09, P = .01). Conclusions: In conclusion, besides comorbidity and age, personality traits—in particular neuroticism—and the coping strategies helplessness/hopelessness, anxious preoccupation, and avoidance were significantly independently associated with psychological distress. Unlike personality, coping strategies are considered to be changeable and could be targeted by interventions such as cognitive behavioral therapy
- …